Table 1. MRD levels for all 17 patients... | American Society of Hematology

Table 1.

MRD levels for all 17 patients at time point 1 (after 15 days of chemotherapy), time point 2 (at the end of induction therapy) and time point 3 (before start of consolidation)

Patient	Outcome	Risk group	% PCR-positive cells^*
Patient	Outcome	Risk group	Time point 1	Time point 2	Time point 3
5902	CCR	SR	1.1	0.01	<0.00001
5524	CCR	SR	0.5	0.006	<0.00001
6110	CCR	SR	1.58	0.01	<0.00001
5400	CCR	MR	1.4	<0.00001	<0.00001
5579	CCR	SR	1.1	0.15	<0.00001
5594	CCR	MR	0.18	<0.00001	<0.00001
6112	CCR	MR	<0.00001	<0.00001	<0.00001
5221	CCR	MR	0.2	0.005	<0.00001
5414	CCR	SR	1.9	0.01	<0.00001
3954	REL	SR	2.6	NT	<0.00001
5292	REL	MR	8	2	NT
3886	REL	HR	14	1.7	0.025
5748	REL	HR	41.7	2.7	4.22
3616	REL	SR	73	1.98	<0.00001
5440	REL	SR	5.3	0.66	NT
5181	REL	MR	3.5	NT	<0.00001
5648	REL	HR	38.5	0.24	NT

Patient	Outcome	Risk group	% PCR-positive cells^*
Patient	Outcome	Risk group	Time point 1	Time point 2	Time point 3
5902	CCR	SR	1.1	0.01	<0.00001
5524	CCR	SR	0.5	0.006	<0.00001
6110	CCR	SR	1.58	0.01	<0.00001
5400	CCR	MR	1.4	<0.00001	<0.00001
5579	CCR	SR	1.1	0.15	<0.00001
5594	CCR	MR	0.18	<0.00001	<0.00001
6112	CCR	MR	<0.00001	<0.00001	<0.00001
5221	CCR	MR	0.2	0.005	<0.00001
5414	CCR	SR	1.9	0.01	<0.00001
3954	REL	SR	2.6	NT	<0.00001
5292	REL	MR	8	2	NT
3886	REL	HR	14	1.7	0.025
5748	REL	HR	41.7	2.7	4.22
3616	REL	SR	73	1.98	<0.00001
5440	REL	SR	5.3	0.66	NT
5181	REL	MR	3.5	NT	<0.00001
5648	REL	HR	38.5	0.24	NT

CCR, continuous complete remission; REL, relapse; SR, standard risk; MR, medium risk; HR, high risk; NT, not tested.

Time point 1 was after 15 days of chemotherapy; time point 2, at the end of induction therapy; and time point 3, before the start of consolidation.

View Large

This Feature Is Available To Subscribers Only